Risk factors and diagnostic tests in drug allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 4, 2007, Pages 297-298

  Thong, Bernard Y H ^a   Blanca, Miguel ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BETA LACTAM DERIVATIVE; CARBAMAZEPINE; HLA ANTIGEN; PENICILLIN G; PENICILLOYL POLYLYSINE;

ALLERGY TEST; ASTHMA; DENDRITIC CELL; DESENSITIZATION; DIAGNOSTIC TEST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EDITORIAL; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTRACUTANEOUS TEST; LYMPHOCYTE TRANSFORMATION; PATCH TEST; PENICILLIN ALLERGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROVOCATION TEST; RISK FACTOR; SKIN TEST; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 34447316983     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32825fea26     Document Type: Editorial

References (15)

1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832-836.
2. Asher I, Baena-Cagnani C, Boner A, et al. World Allergy Organization guidelines for prevention of allergy and allergic asthma. Int Arch Allergy Immunol 2004; 135:83-92.
3. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
4. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006; 8:E20-E26.
5. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306.
6. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-4139.
7. Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
8. Kim SH, Ye YM, Lee SK, et al. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol 2006; 6:266-270.
9. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342.
10. Romano A, Viola M, Bousquet JP, et al. A comparison of the performance of immediate hypersensitivity to betalactams: comparison between two commercial kits. Allergy 2007; 62:53-58.
11. Rodriguez-Bada JL, Montañez MI, Torres MJ, et al. Skin testing for immediate hypersensitivity to betalactams: Comparison of two commercial kits. Allergy 2006; 61:974-1051.
12. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. J Am Med Assoc 1986; 256:3358-3363.
13. Luque I, Leyva L, TorresMJ, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56:611-618.
14. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed hypersensitivity reactions to B-lactams. J Allergy Clin Imunol 2006; 118:949-956.
15. Torres MJ, Padial A, Fuentes MS et al. The role of skin and drug provocation tests in the diagnosis of patients with nonimmediate allergic reactions to betalactams [Abstract]. Proceedings of the European Academy of Allergy and Clinical Immunology Annual Meeting, Amsterdam, 12-16 June, 2004; p. 1023.